Fredun Pharmaceuticals Accelerates Transformation into Branded Healthcare Platform Targeting Rapid Growth
Fredun Pharmaceuticals Ltd · Press Release · 08 Oct 2026, 3:03 pm
Fredun Pharmaceuticals Accelerates Transformation into Branded Healthcare Platform Targeting Rapid Growth Fredun Pharmaceuticals is pivoting from OEM manufacturing to a 100% branded portfolio by 2029, targeting doubled revenue and profitability over the next 3–4 years. Key growth drivers include acquiring a 26% stake in Goodman Vetcare at a ₹300 crore valuation, buying pet-wellness brand Furlicks, and developing the WAGR platform. Manufacturing capacity is expanding with a ~40,000 sq. ft. utility block operational by Oct'26 plus 50,000 sq. ft. planned. Capital base increased following a 1.10 crore bonus share allotment on 17th Jul'26 and warrant conversions.
Original exchange filing (PDF)
More announcements from Fredun Pharmaceuticals Ltd
- Audio Recording Q2 & H1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. · 16 Nov 2026
- Outcome of the Board Meeting of 'Fredun Pharmaceuticals Limited' ('Company') pursuant to Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. · 14 Nov 2026
- Report of Monitoring Agency on the use of proceeds raised through Preferential Allotment for the quarters ended March 31, 2026, June 30,2026 and September30, 2026. · 14 Nov 2026
- Statement of Deviation or Variation For the Quarter Ended September 30, 2026 for the Funds raised through Preferential Issue. · 14 Nov 2026
- Intimation of Earnings Conference Call for the Quarter Q2 of FY27 · 16 Nov 2026
- Press Release · 06 Nov 2026
- Approval for National Stock Exchange of India Limited (NSE) Listing Application. · 05 Nov 2026
- Financial results for the quarter ended 30th September, 2026. · 05 Nov 2026
